tiprankstipranks
Advertisement
Advertisement
BTIG Reiterates Buy on PIKTOR as New PK/PD Data De-Risk Development and Support Unchanged $55 Price Target
PremiumRatingsBTIG Reiterates Buy on PIKTOR as New PK/PD Data De-Risk Development and Support Unchanged $55 Price Target
13d ago
Faeth Therapeutics: Buy Rating Reiterated as PIKTOR Advances in Key Oncology Trials; $60 Price Target Maintained
Premium
Ratings
Faeth Therapeutics: Buy Rating Reiterated as PIKTOR Advances in Key Oncology Trials; $60 Price Target Maintained
19d ago
Faeth Therapeutics management to meet with BTIG
Premium
The Fly
Faeth Therapeutics management to meet with BTIG
20d ago
Faeth Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyFaeth Therapeutics initiated with an Outperform at Oppenheimer
28d ago
Faeth Therapeutics Adopts Performance-Based Stock Option Plan
Premium
Company Announcements
Faeth Therapeutics Adopts Performance-Based Stock Option Plan
1M ago
Faeth Therapeutics initiated with an Outperform at Citizens
Premium
The Fly
Faeth Therapeutics initiated with an Outperform at Citizens
1M ago
Faeth Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyFaeth Therapeutics initiated with a Buy at H.C. Wainwright
2M ago
Faeth Therapeutics Launches New At-the-Market Equity Program
Premium
Company Announcements
Faeth Therapeutics Launches New At-the-Market Equity Program
2M ago
Faeth Therapeutics files automatic mixed securities shelf
Premium
The Fly
Faeth Therapeutics files automatic mixed securities shelf
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100